The U.S. Food and Drug Administration approved Merck's new oral cholesterol-lowering pill, Lipfendra, on Thursday, July 16, 2026 [1, 2].

This approval marks a significant shift in cardiovascular treatment by providing a non-injectable option for high-risk patients. While previous PCSK9 inhibitors required injections, this first-of-its-kind pill allows patients to manage their cholesterol through a daily oral dose [1, 2].

Lipfendra is designed to target the PCSK9 protein to lower low-density lipoprotein, often referred to as "bad" cholesterol. The medication is intended for patients who require more aggressive cholesterol lowering than what standard statins can provide [1, 3].

Medical providers have long sought a way to deliver the potency of PCSK9 inhibitors without the burden of needles. The oral delivery system is expected to increase patient adherence for those at high risk of heart disease [2, 3].

Merck developed the drug to bridge the gap between traditional statins and the more invasive injectable therapies. The FDA's decision allows the drug to enter the U.S. market immediately for authorized use in high-risk populations [1, 2].

Because the drug is an oral PCSK9 inhibitor, it represents a new class of medication in the fight against atherosclerosis. This development provides a new tool for physicians treating patients who are either intolerant to statins, or fail to reach target cholesterol levels through traditional means [2, 3].

“The FDA approved Merck's new oral cholesterol-lowering pill, Lipfendra.”

The approval of Lipfendra removes a primary barrier to the use of PCSK9 inhibitors: the need for injections. By transitioning this high-potency mechanism into a pill, the medical community may see a higher rate of treatment compliance among high-risk cardiovascular patients, potentially reducing the long-term incidence of heart attacks and strokes in populations that do not respond to statins.